Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 101557015 | 10155701 | 5 | F | 20140103 | 20160822 | 20140506 | 20160826 | EXP | UG-GILEAD-2014-0101523 | GILEAD | 41.00 | YR | A | M | Y | 73.00000 | KG | 20160826 | OT | UG | UG |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 101557015 | 10155701 | 1 | PS | EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE | EFAVIRENZEMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | 1100 MG, QD | 179300 | MG | Y | 21937 | 1100 | MG | TABLET | QD | |||
| 101557015 | 10155701 | 2 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Oral | 50 MG, QD | 5200 | MG | 0 | 50 | MG | QD | |||||
| 101557015 | 10155701 | 3 | C | CEFTRIAXONE. | CEFTRIAXONE | 1 | Intravenous (not otherwise specified) | U | 0 | ||||||||||
| 101557015 | 10155701 | 4 | C | PACLITAXEL. | PACLITAXEL | 1 | Unknown | 190 MG, UNK | U | 0 | 190 | MG | |||||||
| 101557015 | 10155701 | 5 | C | PACLITAXEL. | PACLITAXEL | 1 | Unknown | 235 UNK, UNK | U | 0 | 235 | MG | |||||||
| 101557015 | 10155701 | 6 | C | DEXAMETHAZONE | DEXAMETHASONE | 1 | Intravenous (not otherwise specified) | UNK | U | 0 | |||||||||
| 101557015 | 10155701 | 7 | C | DEXAMETHAZONE | DEXAMETHASONE | 1 | UNK | U | 0 | ||||||||||
| 101557015 | 10155701 | 8 | C | METOCLOPRAMIDE. | METOCLOPRAMIDE | 1 | Intravenous (not otherwise specified) | UNK | U | 0 | |||||||||
| 101557015 | 10155701 | 9 | C | METOCLOPRAMIDE. | METOCLOPRAMIDE | 1 | Intravenous (not otherwise specified) | UNK | U | 0 | |||||||||
| 101557015 | 10155701 | 10 | C | SULFAMETHOXAZOLE AND TRIMETHOPRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 101557015 | 10155701 | 1 | HIV infection |
| 101557015 | 10155701 | 2 | Kaposi's sarcoma AIDS related |
| 101557015 | 10155701 | 10 | Prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 101557015 | 10155701 | OT |
| 101557015 | 10155701 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 101557015 | 10155701 | Acute kidney injury | |
| 101557015 | 10155701 | Anaemia | |
| 101557015 | 10155701 | Bacteraemia | |
| 101557015 | 10155701 | Kaposi's sarcoma | |
| 101557015 | 10155701 | Urinary tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 101557015 | 10155701 | 1 | 20130724 | 20140423 | 0 | |
| 101557015 | 10155701 | 2 | 20130725 | 20131106 | 0 | |
| 101557015 | 10155701 | 4 | 20140508 | 0 | ||
| 101557015 | 10155701 | 5 | 20140515 | 0 | ||
| 101557015 | 10155701 | 6 | 20140508 | 0 | ||
| 101557015 | 10155701 | 7 | 20140515 | 0 | ||
| 101557015 | 10155701 | 8 | 20140508 | 0 | ||
| 101557015 | 10155701 | 9 | 20140515 | 0 |